95 related articles for article (PubMed ID: 17112803)
1. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
[TBL] [Abstract][Full Text] [Related]
2. Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.
Benz-de Bretagne I; Zahr N; Le Gouge A; Hulot JS; Houillier C; Hoang-Xuan K; Gyan E; Lissandre S; Choquet S; Le Guellec C
Br J Clin Pharmacol; 2014 Aug; 78(2):329-42. PubMed ID: 24433481
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia.
de Oliveira Henz P; Pinhatti AV; Gregianin LJ; Martins M; Curra M; de Araújo BV; Dalla Costa T
Pharm Res; 2023 Jul; 40(7):1777-1787. PubMed ID: 37291462
[TBL] [Abstract][Full Text] [Related]
4. The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.
Beechinor RJ; Thompson PA; Hwang MF; Vargo RC; Bomgaars LR; Gerhart JG; Dreyer ZE; Gonzalez D
Clin Pharmacokinet; 2019 Jul; 58(7):899-910. PubMed ID: 30810947
[TBL] [Abstract][Full Text] [Related]
5. Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: The Petale study.
Petrykey K; Lippé S; Robaey P; Sultan S; Laniel J; Drouin S; Bertout L; Beaulieu P; St-Onge P; Boulet-Craig A; Rezgui A; Yasui Y; Sapkota Y; Krull KR; Hudson MM; Laverdière C; Sinnett D; Krajinovic M
PLoS One; 2019; 14(6):e0217314. PubMed ID: 31181069
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia.
Gurieva OD; Savelyeva MI; Valiev TT; Sozaeva ZA; Kondratenko SN; Ilyin MV
Drug Metab Pers Ther; 2023 Dec; 38(4):349-357. PubMed ID: 38098143
[TBL] [Abstract][Full Text] [Related]
7. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.
Taylor ZL; Miller TP; Poweleit EA; DeGroote NP; Pommert L; Awoniyi O; Board SG; Ugboh N; Joshi V; Ambrosino N; Chavana A; Bernhardt MB; Schafer ES; O'Brien MM; Castellino SM; Ramsey LB
Clin Transl Sci; 2023 Nov; 16(11):2130-2143. PubMed ID: 37503924
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.
Chen WQ; Shu Y; Li Q; Xu LY; Roederer MW; Fan L; Wu LX; He FZ; Luo JQ; Tan ZR; He YJ; Zhou HH; Chen X; Zhang W
PLoS One; 2013; 8(8):e70341. PubMed ID: 23940561
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
[TBL] [Abstract][Full Text] [Related]
10. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
[TBL] [Abstract][Full Text] [Related]
11. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
13. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
14. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
15. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
17. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
18. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
Simon N; Marsot A; Villard E; Choquet S; Khe HX; Zahr N; Lechat P; Leblond V; Hulot JS
Pharmacogenomics J; 2013 Dec; 13(6):507-13. PubMed ID: 23069858
[TBL] [Abstract][Full Text] [Related]
19. Association of
Razali RH; Noorizhab MNF; Jamari H; James RJ; Teh KH; Ibrahim HM; Teh LK; Salleh MZ
Pediatr Hematol Oncol; 2020 Apr; 37(3):185-197. PubMed ID: 31870219
[TBL] [Abstract][Full Text] [Related]
20. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]